デフォルト表紙
市場調査レポート
商品コード
1304270

ドラッグデリバリーと遺伝子送達デバイス市場:製品別、市販薬別、地域別:規模、シェア、展望、機会分析、2023年~2030年

Drug and Gene Delivery Devices Market, By Product, By Commercialized Drugs (Luxturna, Yescarta, Zolgensma, Kymriah, Provenge, and Strimvelis ), and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 155 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ドラッグデリバリーと遺伝子送達デバイス市場:製品別、市販薬別、地域別:規模、シェア、展望、機会分析、2023年~2030年
出版日: 2023年06月19日
発行: Coherent Market Insights
ページ情報: 英文 155 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

ドラッグデリバリーと遺伝子送達デバイスの分野では、最終的に細胞、組織、生体のタンパク質発現や機能を変化させる薬物、遺伝子、および/または遺伝子産物の開発とデリバリーが含まれます。ドラッグデリバリーデバイスは、特定の投与経路を通して薬物を送達するために使用されるツールです。一方、遺伝子送達は、DNAやRNAのような外来の遺伝物質を宿主細胞に導入するプロセスです。

市場力学:

感染症、心血管疾患、がん、糖尿病などの慢性疾患の負担の増加、ドラッグデリバリーや遺伝子送達装置に対する需要の増加、細胞治療や遺伝子治療に対する資金提供の増加、遺伝子治療の承認の増加は、予測期間中に世界のドラッグデリバリーと遺伝子送達デバイス市場の成長を増大させると予想される主な要因です。

例えば、2022年11月、Imunon, Inc.とAcuitas Therapeutics社は、IMUNON社のPLACCINE核酸ワクチンコンストラクトとAcuitas社独自の脂質デリバリー技術の組み合わせを評価する契約を締結しました。本契約に基づき、IMUNON社はAcuitas社の様々なLNP製剤に製剤化したベクターコンストラクトを投与し、マウスモデルにおける遺伝子発現と免疫原性を評価します。

この研究の主な特徴

  • 本レポートは、世界のドラッグデリバリーと遺伝子送達デバイス機器市場を詳細に分析し、2022年を基準年とした予測期間(2023-2030年)の市場規模および複合年間成長率(CAGR%)を提供しています。
  • また、さまざまなセグメントにわたる潜在的な収益機会を解明し、この市場に対する魅力的な投資提案のマトリックスについて説明しています。
  • また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
  • 企業ハイライト、製品ポートフォリオ、主要ハイライト、財務実績、戦略などの以下のパラメータに基づいて、世界のドラッグデリバリーと遺伝子送達デバイス機器市場の主要企業をプロファイルしています。
  • 本調査の対象となる主要企業には、Pfizer, Inc., Novartis AG, Kite Pharma, Inc., Bluebird bio, Inc., Becton, Amgen, Inc., Vericel Corporation, uniQure N.V., Spark Therapeutics, Inc., Renova Therapeutics, Orchard Therapeutics plc, Kolon Tissue Gene, Inc., Human Stem Cell Institute, Dendreon Pharmaceuticals, Dickinson and Company, Helixmith Co., Ltd(ViroMed Co., Ltd), Bausch & Lomb Incorporated, and Castle Creek Biosciences, Inc(Fibrocell Technologies, Inc.), among others.が含まれます。
  • 本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
  • この調査レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入企業、財務アナリストなど、この業界のさまざまな利害関係者を対象としています。
  • 利害関係者は、世界のドラッグデリバリーデバイス市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場概況

  • レポート概要
    • 市場の定義と範囲
  • エグゼクティブサマリー
  • コヒーレント・オポチュニティ・マップ(COM)

第3章 市場力学、規制、動向分析

  • 市場力学
    • 世界中で慢性疾患の負担が増加
    • 厳しい規則と規制
    • ドラッグデリバリーと遺伝子送達デバイスの需要増加
  • 影響分析
  • 主なハイライト
  • 規制シナリオ
  • 製品上市/承認
  • PEST分析
  • ポーターズ分析
  • 合併・買収シナリオ

第4章 ドラッグデリバリーと遺伝子送達デバイスの世界市場-コロナウイルス(COVID-19)流行の影響

  • COVID-19疫学
  • 供給サイドと需要サイドの分析
  • 経済的影響

第5章 ドラッグデリバリーと遺伝子送達デバイスの世界市場:製品別、2018-2030年

  • 網膜下注入カニューレ
  • 延長チューブ
  • 静脈カテーテル
  • 滅菌インスリンシリンジ
  • プレフィルドシリンジ
  • 輸液バッグ

第6章 ドラッグデリバリーと遺伝子送達デバイスの世界市場:市販薬別、2018年~2030年

  • Luxturna(ドラッグデリバリーデバイス)
  • イエスカルタ(ドラッグデリバリーデバイス)
  • ゾルゲンマ(ドラッグデリバリー機器)
  • キムリア(ドラッグデリバリーデバイス)
  • プロベンジ(ドラッグデリバリー機器)
  • ストリムベリス(ドラッグデリバリー機器)

第7章 ドラッグデリバリーと遺伝子送達デバイスの世界市場:地域別、2018年~2030年

  • 北米
  • ラテンアメリカ
  • 欧州
  • アジア太平洋
  • 中東
  • アフリカ

第8章 競合情勢

  • Pfizer, Inc.
  • Novartis AG
  • Kite Pharma, Inc.
  • Bluebird bio, Inc.
  • Vericel Corporation
  • uniQure N.V.
  • Spark Therapeutics, Inc.
  • Renova Therapeutics
  • Orchard Therapeutics plc
  • Kolon Tissue Gene, Inc.
  • Human Stem Cell Institute
  • Amgen, Inc.
  • Dendreon Pharmaceuticals
  • Helixmith Co.
  • Bausch & Lomb Incorporated, Ltd.(ViroMed Co., Ltd.)
  • Becton Dickinson and Company
  • Castle Creek Biosciences, Inc.(Fibrocell Technologies, Inc.)

第9章 セクション

  • 調査手法
  • 出版社について
目次
Product Code: CMI5864

The field of drug and gene delivery involves the development and delivery of drugs, genes, and/or gene products that ultimately alter protein expression and function of the cells, tissues, and living organisms. Drug delivery devices are the tools used to deliver the drug through the specific route of administration. While, gene delivery is the process of introducing foreign genetic material, such as DNA or RNA, into host cells.

Market Dynamics:

Rise in burden of chronic diseases, such as infectious disease, cardiovascular disease, cancer, and diabetes, increasing demand for drug or gene delivery devices, increasing funding for cell and gene therapies, and rise in approvals for gene therapies are major factors expected to augment the growth of the global drug and gene delivery devices market over the forecast period.

For instance, in November 2022, Imunon, Inc. and Acuitas Therapeutics signed an agreement to evaluate the combination of IMUNON's PLACCINE nucleic acid vaccine constructs formulated with Acuitas' proprietary lipid delivery technology. Under the agreement, IMUNON will evaluate administration of its vector constructs formulated in various Acuitas LNP formulations for gene expression and immunogenicity in murine models.

Key features of the study:

  • This report provides in-depth analysis of the global drug and gene delivery devices market, and provides market size (US$ Thousand) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global drug and gene delivery devices market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer, Inc., Novartis AG, Kite Pharma, Inc., Bluebird bio, Inc., Becton, Amgen, Inc., Vericel Corporation, uniQure N.V., Spark Therapeutics, Inc., Renova Therapeutics, Orchard Therapeutics plc, Kolon Tissue Gene, Inc., Human Stem Cell Institute, Dendreon Pharmaceuticals, Dickinson and Company, Helixmith Co., Ltd (ViroMed Co., Ltd), Bausch & Lomb Incorporated, and Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global drug and gene delivery devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global drug and gene delivery devices market.

Detailed Segmentation:

  • Global Drug and Gene Delivery Devices Market, By Product:
    • Sub-retinal Injection Cannula
    • Extension Tube
    • Intravenous Catheter
    • Sterile Insulin Syringe
    • Pre-filled Syringe
    • Infusion Bags
  • Global Drug and Gene Delivery Devices Market, By Commercialized Drugs:
    • Luxturna (Drug Delivery Devices)
    • Yescarta (Drug Delivery Devices)
    • Zolgensma (Drug Delivery Devices)
    • Kymriah (Drug Delivery Devices)
    • Provenge (Drug Delivery Devices)
    • Strimvelis (Drug Delivery Devices)
  • Global Drug and Gene Delivery Devices Market, By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles:
    • Pfizer, Inc.
    • Novartis AG
    • Kite Pharma, Inc.
    • Bluebird bio, Inc.
    • Becton Dickinson and Company
    • Amgen, Inc.
    • Vericel Corporation
    • uniQure N.V.
    • Spark Therapeutics, Inc.
    • Renova Therapeutics
    • Orchard Therapeutics plc
    • Kolon Tissue Gene, Inc.
    • Human Stem Cell Institute
    • Dendreon Pharmaceuticals
    • Helixmith Co., Ltd (ViroMed Co., Ltd.)
    • Bausch & Lomb Incorporated
    • Castle Creek Biosciences, Inc. (Fibrocell Technologies, Inc.)

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Product
    • Market Snapshot, By Commercialized Drugs
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rise in burden of chronic diseases across the globe
    • Stringent rules and regulations
    • Increasing demand for drug and gene delivery devices
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Drug and Gene Delivery Devices Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Drug and Gene Delivery Devices Market, By Product, 2018-2030, (US$ Thousand)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Sub-retinal Injection Cannula
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Extension Tube
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Intravenous Catheter
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Sterile Insulin Syringe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Pre-filled Syringe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Infusion Bags
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)

6. Global Drug and Gene Delivery Devices Market, By Commercialized Drugs, 2018-2030, (US$ Thousand)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Luxturna (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Yescarta (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Zolgensma (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Kymriah (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Provenge (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Strimvelis (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)

7. Global Drug and Gene Delivery Devices Market, By Region, 2018-2030, (US$ Thousand)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2018-2030,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2018-2030,(US$ Thousand)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2018-2030,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2018-2030,(US$ Thousand)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2018-2030,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2018-2030,(US$ Thousand)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2018-2030,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2018-2030,(US$ Thousand)
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2018-2030,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2018-2030,(US$ Thousand)
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2018-2030,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2018-2030,(US$ Thousand)

8. Competitive Landscape

  • Pfizer, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Kite Pharma, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bluebird bio, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Vericel Corporation
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • uniQure N.V.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Spark Therapeutics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Renova Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Orchard Therapeutics plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Kolon Tissue Gene, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Human Stem Cell Institute
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amgen, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Dendreon Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Helixmith Co.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bausch & Lomb Incorporated, Ltd. (ViroMed Co., Ltd.)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Becton Dickinson and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Castle Creek Biosciences, Inc. (Fibrocell Technologies, Inc.)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us